Baxter Halts Shipments of Novum LVP After Reports of Injuries and Deaths Linked to Device Safety Issues
Baxter International Inc. has announced significant safety concerns with its Novum Large Volume Pump (LVP) medical device, following reports of inaccurate infusion rates leading to both under infusion and over infusion. The company disclosed that it has received 79 reports of serious injuries and two patient deaths related to the device. On July 31, 2025, Baxter announced a voluntary and temporary pause on shipments and planned installations of the Novum LVP, citing issues identified through quality monitoring systems and customer feedback. Despite earlier warnings and corrective instructions to hospitals, Baxter is currently unable to commit to a timeline for resuming shipments. Following the announcement, the company's stock price dropped by more than 22%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Baxter International Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1095830) on November 03, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。